SAVA Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -- compared to Cassava Sciences's net margin of 50.24%. Cassava Sciences's return on equity of -- beat Johnson & Johnson's return on equity of 30.18%.

Cassava Sciences has a consensus price target of $2.00, signalling upside risk potential of 9.29%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 11.3%. Given that Johnson & Johnson has higher upside potential than Cassava Sciences, analysts believe Johnson & Johnson is more attractive than Cassava Sciences.

Cassava Sciences has a beta of -1.994, which suggesting that the stock is 299.436% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.846%.

Cassava Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.3% to investors and pays a quarterly dividend of $1.30 per share. Cassava Sciences pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cassava Sciences quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Cassava Sciences's net income of -$23.4M is lower than Johnson & Johnson's net income of $11B. Notably, Cassava Sciences's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 16.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences is 2.12x versus 4.13x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Cassava Sciences's net margin of 21.68%. Cassava Sciences's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Cassava Sciences has a consensus price target of $2.00, signalling upside risk potential of 9.29%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 19.73%. Given that Eli Lilly and has higher upside potential than Cassava Sciences, analysts believe Eli Lilly and is more attractive than Cassava Sciences.

Cassava Sciences has a beta of -1.994, which suggesting that the stock is 299.436% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

Cassava Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.7% to investors and pays a quarterly dividend of $1.50 per share. Cassava Sciences pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cassava Sciences quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Cassava Sciences's net income of -$23.4M is lower than Eli Lilly and's net income of $2.8B. Notably, Cassava Sciences's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences is 2.12x versus 14.66x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Cassava Sciences's net margin of 32.71%. Cassava Sciences's return on equity of -- beat Merck &'s return on equity of 39.02%.

Cassava Sciences has a consensus price target of $2.00, signalling upside risk potential of 9.29%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 29.12%. Given that Merck & has higher upside potential than Cassava Sciences, analysts believe Merck & is more attractive than Cassava Sciences.

Cassava Sciences has a beta of -1.994, which suggesting that the stock is 299.436% less volatile than S&P 500. In comparison Merck & has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.863%.

Cassava Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.06% to investors and pays a quarterly dividend of $0.81 per share. Cassava Sciences pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cassava Sciences quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Cassava Sciences's net income of -$23.4M is lower than Merck &'s net income of $5.1B. Notably, Cassava Sciences's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences is 2.12x versus 3.13x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Cassava Sciences's net margin of -49.65%. Cassava Sciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cassava Sciences has a consensus price target of $2.00, signalling upside risk potential of 9.29%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that NovaBay Pharmaceuticals has higher upside potential than Cassava Sciences, analysts believe NovaBay Pharmaceuticals is more attractive than Cassava Sciences.

Cassava Sciences has a beta of -1.994, which suggesting that the stock is 299.436% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Cassava Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cassava Sciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cassava Sciences's net income of -$23.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Cassava Sciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences is 2.12x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.